Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Institut de Cancérologie de Lorraine
Massachusetts General Hospital
Massachusetts General Hospital
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Alliance for Clinical Trials in Oncology
Dana-Farber Cancer Institute
Bayer
First Affiliated Hospital, Sun Yat-Sen University
Jinling Hospital, China
Emory University
First Affiliated Hospital, Sun Yat-Sen University
Erasme University Hospital
Centre Francois Baclesse, Luxembourg
Massachusetts General Hospital
H. Lee Moffitt Cancer Center and Research Institute
Medical University of Silesia
Celgene
Universitätsklinikum Hamburg-Eppendorf
NYU Langone Health
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
CHIR-Net
National Cancer Institute (NCI)
Institut Paoli-Calmettes
National Cancer Institute (NCI)
Indiana University
Southwestern Regional Medical Center
Karolinska Institutet
Karolinska Institutet
NYU Langone Health